Recent 8-K filings for INSP

• May 4, 2026, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 7.01item 9.01 ◈ Earnings Releases ×2

  Inspire Medical Q1 revenue up 1.6% to $204.6M; guides FY2026 revenue down 4-10%

  GAAP diluted EPS $(0.39); adjusted diluted EPS $0.10; operating cash flow $12.8M.

• February 11, 2026, 6:59 PM ET earnings materiality 0.85 negative item 2.02item 5.03item 7.01item 9.01 ◈ Governance Changes ×2

  Inspire Q4 rev $269M (+12%), EPS $4.66; FY26 outlook lowered on coding change

  Q4 revenue $269.1M (+12%); GAAP diluted EPS $4.66; adjusted EPS $1.65.

• January 12, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 5.02item 7.01item 9.01

  Inspire Medical posts preliminary Q4 rev ~$269M (+12% YoY); 2026 guidance $1,003-1,013M

  Preliminary Q4 2025 revenue ~$269M, up 12% YoY; full-year 2025 revenue ~$912M, up 14% YoY.

• November 17, 2025, 6:59 PM ET other material materiality 0.85 positive item 8.01

  Inspire Medical Systems expects $90M-$100M tax benefit from valuation allowance release

  Company disclosed expectation to release a significant portion of valuation allowance on U.S. deferred tax assets.

• November 3, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  Inspire Medical Q3 revenue $224.5M (+10% YoY); net income down; FY25 EPS guidance raised to $0.90-$1.00

  Revenue $224.5M in Q3 2025, up 10% from $203.2M a year ago; U.S. revenue $214.4M (+9%), OUS revenue $10.1M (+37%).

• October 10, 2025, 7:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  Inspire V clinical data shows superior efficacy, adherence, and reduced surgical times; AHI cut from 34.4 to 8.3

  Singapore study (44 patients): Inspire V IPOP 87.1% vs Inspire IV 79.4%, exceeding non-inferiority margin of 4.6%.

• August 26, 2025, 7:59 PM ET leadership materiality 0.65 neutral item 5.02item 7.01item 9.01

  Inspire Medical Systems CFO Rick Buchholz to step down by Dec 31, 2025; 2025 guidance reaffirmed

  CFO Rick Buchholz resigns effective Dec 31, 2025, will remain in advisory role through Feb 28, 2026.

• August 11, 2025, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Inspire Medical Systems board authorizes $200M share repurchase program

  Board authorized repurchase of up to $200M of common stock.

• August 4, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 5.02item 7.01item 9.01

  Inspire Medical Q2 net loss $3.6M, cuts FY 2025 revenue guidance to $900-910M

  Q2 revenue $217.1M (+11% YoY), net loss $3.6M vs prior year net income $9.8M.

• May 5, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Inspire Medical Q1 rev $201.3M (+23% YoY), EPS $0.10; raises FY EPS guidance to $2.20-$2.30

  Revenue $201.3M, up 23% YoY; U.S. revenue $193.6M (+24%), OUS $7.7M (-6%).

• February 10, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Inspire Medical Q4 revenue $239.7M (+25% YoY); EPS $1.15; guides FY2025 rev $940-955M

  Q4 revenue $239.7M (+25% YoY); net income $35.2M, diluted EPS $1.15 vs $0.49 prior year.

• January 13, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Inspire Medical reports Q4 revenue ~$239.7M (+25% YoY); issues 2025 guidance $940-955M

  Preliminary Q4 2024 revenue ~$239.5-239.7M, up 25% YoY; full year 2024 revenue ~$802.6-802.8M, up 28% YoY.

• November 4, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Inspire Medical Q3 revenue $203.2M (+33% YoY), EPS $0.60 vs loss, raises FY guidance

  Revenue $203.2M, up 33% YoY; U.S. revenue $195.8M (+33%), OUS $7.4M (+27%).

• August 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 8.01item 9.01

  Inspire Q2 revenue $195.9M (+30% YoY), EPS $0.32; raises FY guide, authorizes $150M buyback

  Q2 revenue $195.9M (30% YoY), net income $9.8M vs loss $12.0M; diluted EPS $0.32 vs ($0.41).

• August 2, 2024, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  Inspire Medical receives FDA approval for next-gen Inspire V neurostimulation system

  FDA approved Inspire V system including next-generation neurostimulator, Bluetooth patient remote, and physician programmer.

• July 29, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Inspire Medical pre-announces Q2 revenue $195.9M (+30% YoY), raises 2024 guidance to $788-798M

  Q2 revenue $195.9M, up 30% YoY; US revenue $187.8M (+30%), OUS $8.1M (+27%).

• May 7, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases ×2

  Inspire Medical Q1 revenue $164M (+28% YoY); raises FY2024 guidance, expects full-year profitability

  Q1 2024 revenue $164.0M, up 28% YoY; net loss narrowed to $10.0M ($0.34/share) from $15.4M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.80 · Most common event earnings

12 positive 3 negative 8 neutral

source · INSP on sec.gov